Archives
ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
Superior and clinically meaningful reduction in body weight in adults with overweight, obesity without type 2 diabetes
ENDO: Women With Polycystic Ovary Syndrome Experience More Body Image Concerns
Authors say findings show need for body image screening in clinical practice
ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
Substantial and clinically meaningful reductions in body weight seen for adults with obesity and type 2 diabetes
ADA: Bempedoic Acid Cuts MACE in Statin-Intolerant Patients
Significant risk reduction in primary end point of composite of cardiovascular death nonfatal myocardial infarction, nonfatal stroke, coronary revascularization
ADA: Once-Daily Orforglipron Linked to Significant Weight Reduction
Weight reduction of at least 10 percent occurred in 46 to 75 percent receiving orforglipron by week 36
ADA: Glycemic Control Up With Weekly Icodec Versus Daily Insulin Glargine
Findings in adults with type 2 diabetes who had not previously received insulin
Continuous Meropenem No Benefit in Critically Ill Patients With Sepsis
No improvement seen in composite of all-cause mortality and emergence of pandrug- or extensively drug-resistant bacteria
ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events
Findings seen in middle-aged men with preexisting or high risk of cardiovascular disease and hypogonadism
Successful Intubation on First Attempt Improved With Video Laryngoscopy
Findings seen for critically ill adults undergoing tracheal intubation
Lower Mortality Seen With Hemodiafiltration for Kidney Failure
Risk for death from any cause reduced with hemodiafiltration versus hemodialysis among patients with kidney failure
